中国组织工程研究 ›› 2022, Vol. 26 ›› Issue (31): 4988-4995.doi: 10.12307/2022.992

• 肿瘤干细胞 cancer stem cells • 上一篇    下一篇

中药复方敷和备化方对CD133+HepG2肝癌干细胞增殖及相关自噬蛋白影响的机制

李祖隆1,荣  震2,孙  华1,蒋锐沅1,钟晓婷1,莫春梅2   

  1. 1广西中医药大学,广西壮族自治区南宁市   530023;2深圳市宝安纯中医治疗医院,广东省深圳市   518100
  • 收稿日期:2021-08-05 接受日期:2021-10-15 出版日期:2022-11-08 发布日期:2022-04-24
  • 通讯作者: 莫春梅,硕士,主任医师,深圳市宝安纯中医治疗医院,广东省深圳市 518100
  • 作者简介:李祖隆,男,1993年生,广西壮族自治区梧州市人,汉族,广西中医药大学在读硕士,主要从事中医药防治恶性肿瘤研究。
  • 基金资助:
    国家自然科学基金项目(81760850),项目负责人:莫春梅;广西中医药大学第一附属医院院内制剂研究与开发项目(2018ZJ004),项目负责人:莫春梅;国家科技重大专项课题(2018ZX10303502-001,2018ZX10303502-002),项目参与人:莫春梅

Mechanism underlying the effect of Fuhebeihua Recipe on the proliferation of CD133+HepG2 hepatoma stem cells and related autophagy proteins

Li Zulong1, Rong Zhen2, Sun Hua1, Jiang Ruiyuan1, Zhong Xiaoting1, Mo Chunmei2   

  1. 1Guangxi University of Chinese Medicine, Nanning 530023, Guangxi Zhuang Autonomous Region, China; 2Shenzhen Baoanchun Traditional Chinese Medicine Treatment Hospital, Shenzhen 518100, Guangdong Province, China
  • Received:2021-08-05 Accepted:2021-10-15 Online:2022-11-08 Published:2022-04-24
  • Contact: Mo Chunmei, Master, Chief physician, Shenzhen Baoanchun Traditional Chinese Medicine Treatment Hospital, Shenzhen 518100, Guangdong Province, China
  • About author:Li Zulong, Master candidate, Guangxi University of Chinese Medicine, Nanning 530023, Guangxi Zhuang Autonomous Region, China
  • Supported by:
    National Natural Science Foundation of China, No. 81760850 (to MCM); In-Hospital Preparation Research and Development of the First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 2018ZJ004 (to MCM); National Science and Technology Major Special Project, No. 2018ZX10303502-001, 2018ZX10303502-002 (to MCM)

摘要:

文题释义:
肝癌干细胞:是存在于肝癌细胞中一个微小群体,具有很强的自我更新能力和多分化潜能,在肝癌的发生发展、复发和转移中都起着十分重要的作用。肝癌细胞的干性是肝癌产生复发、转移和化学抗性的主要原因,也是肿瘤治疗的主要障碍。随着研究的深入,肝癌干细胞被认为是治疗肝癌的一个重要靶点,也是肿瘤细胞维持高增殖水平、高侵袭水平的关键。
自噬:是一个吞噬自身细胞质蛋白或细胞器并使其包被进入囊泡,与溶酶体融合形成自噬溶酶体,降解其所包裹内容物的过程,借此实现细胞本身的代谢需要和某些细胞器的更新。肝癌发生自噬能够促使肝癌细胞维持高代谢水平和高侵袭转移水平,并能通过细胞自噬以实现对化疗药物的逃避杀伤。

背景:肝癌干细胞是肝癌不断发生发展和高异质性产生的关键细胞,目前尚无针对肝癌干细胞相关自噬通路为靶点的中药复方研究,因此中药复方抑制肝癌干细胞自噬的研究十分具有必要性。
目的:探讨中药复方制剂敷和备化方对CD133+HepG2肝癌干细胞PI3K/AKT/mTOR通路及相关自噬蛋白影响的机制。
方法:免疫磁珠法分选出CD133+HepG2细胞,用体积分数为2%,4%,8%,16%敷和备化方含药血清作用CD133+HepG2细胞,CCK-8法检测细胞增殖活力,选出最佳干预体积分数的敷和备化方含药血清。将CD133+HepG2细胞分为血清对照组、空白对照组、雷帕霉素组和敷和备化方组,分别用含体积分数16%空白大鼠血清的DMEM/F12培养基、无血清DMEM/F12培养基、含0.05%雷帕霉素的DMEM/F12培养基、含体积分数16%敷和备化方含药血清的DMEM/F12培养基培养。流式细胞术检测各组CD133+HepG2肝癌干细胞百分比;RT-PCR法检测各组细胞中PI3K、AKT、mTOR、LC3-Ⅱ、Beclin-1的mRNA表达水平;Western blot 法检测各组细胞中PI3K、p-AKT、AKT、p-mTOR、mTOR、LC3-Ⅱ的蛋白表达水平;免疫荧光法检测各组细胞中LC3、LC3-Ⅱ的表达水平。
结果与结论:①敷和备化方含药血清有抑制CD133+HepG2细胞增殖的作用,其中体积分数为16%敷和备化方含药血清干预72 h抑制作用最明显(P < 0.05);②与血清对照组、空白对照组相比,敷和备化方组和雷帕霉素组CD133+HepG2细胞百分比下降(P < 0.05),PI3K、AKT、p-mTOR、mTOR、LC3-Ⅱ的蛋白表达水平均明显下调(P < 0.05);PI3K、AKT、mTOR、LC3-Ⅱ、Beclin-1的mRNA表达水平均明显下调(P < 0.05);LC3、LC3-Ⅱ的荧光信号强度均明显下调(P < 0.05);③与雷帕霉素组相比,敷和备化方组CD133+HepG2细胞中的PI3K、p-AKT、AKT、p-mTOR、mTOR、LC3-Ⅱ蛋白表达水平均明显下调(P < 0.05),PI3K、AKT、mTOR、LC3-Ⅱ、Beclin-1的mRNA表达水平均明显下调(P < 0.05), LC3、LC3-Ⅱ的荧光信号强度均明显下调(P < 0.05);④结果表明,敷和备化方能抑制肝癌干细胞自噬和增殖,其机制与抑制PI3K/AKT/mTOR信号通路有关。

https://orcid.org/0000-0001-7387-2588 (李祖隆)

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

关键词: 肝癌干细胞, 敷和备化方, PI3K, AKT, mTOR, 通路, LC3, 自噬

Abstract: BACKGROUND: Hepatoma stem cells are key cells for the continuous development and high heterogeneity of liver cancer. At present, there is no research on Chinese medicine compound that targets hepatoma stem cell-related autophagy pathways. Therefore, it is very necessary to study Chinese medicine compound prescription to inhibit hepatoma stem cell autophagy.  
OBJECTIVE: To investigate the effect and mechanism of Fuhebeihua Recipe on PI3K/AKT/mTOR pathway and related autophagy proteins in CD133+HepG2 hepatoma stem cells.
METHODS:  CD133+HepG2 cells were selected by immunomagnetic bead method. CD133+HepG2 cells were treated with different volume fractions of Fuhebeihua Recipe-containing serum of 2%, 4%, 8%, and 16%. The cell proliferation activity was detected by CCK-8 assay. The best volume fraction of Fuhebeihua Recipe-containing serum was selected. CD133+HepG2 cells were divided into blank control group, serum control group, rapamycin group, and Fuhebeihua Recipe group. Cells were separately cultured with DMEM/F12 containing serum of 16%, serum-free DMEM/F12, DMEM/F12 containing 0.05% rapamycin, and DMEM/F12 with Fuhebeihua Recipe-containing serum of 16%. The percentage of CD133+HepG2 hepatoma stem cells was detected by flow cytometry in each group. The mRNA expression levels of PI3K, AKT, mTOR, LC3-II, and beclin-1 were detected by RT-PCR. The protein expression levels of PI3K, p-AKT, AKT, p-mTOR, mTOR, and LC3-II were detected by western blot assay. The expression levels of LC3 and LC3-II were detected by immunofluorescence in each group.  
RESULTS AND CONCLUSION: (1) The Fuhebeihua Recipe-containing serum inhibited the proliferation of CD133+HepG2 cells, and the inhibitory effect was the most obvious when the volume fraction was 16% (P < 0.05). (2) Compared with serum control group and blank control group, the percentage of CD133+HepG2 cells reduced (P < 0.05); protein expression levels of PI3K, AKT, p-mTOR, mTOR, and LC3-II were significantly decreased (P < 0.05); mRNA expression levels of PI3K, AKT, mTOR, LC3-II, and Beclin-1 were significantly down-regulated (P < 0.05); the fluorescence signal intensities of LC3 and LC3-II were significantly down-regulated (P < 0.05) in the Fuhebeihua Recipe group and rapamycin group. (3) Compared with the rapamycin group, the protein expression levels of PI3K, p-Akt, AKT, p-mTOR, mTOR, and LC3-II in CD133+HepG2 cells were significantly down-regulated (P < 0.05); the mRNA expression levels of PI3K, AKT, mTOR, LC3-II, and Beclin-1 were significantly decreased (P < 0.05); the fluorescence signal intensities of LC3 and LC3-II were significantly decreased in the Fuhebeihua Recipe group (P < 0.05). (4) It is concluded that Fuhebeihua Recipe can inhibit autophagy and proliferation of hepatoma stem cells, and its mechanism is related to the inhibition of PI3K/AKT/mTOR signaling pathway.

Key words: hepatoma stem cells, Fuhebeihua Recipe, PI3K, AKT, mTOR, pathway, LC3, autophagy

中图分类号: